摩根士丹利维持辉瑞 (PFE) 同等权重评级，强调专利担忧

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The agreement extends U.S. exclusivity for Vyndamax to June 1, 2031. The firm said that, based on recent conversations, this outcome sits at the lower end of investor expectations of 2031/2032.

该内容为新闻快讯，正文已简化。